JNY logo

JW (Cayman) Therapeutics DB:JNY Stock Report

Last Price

€0.25

Market Cap

€107.6m

7D

-11.2%

1Y

n/a

Updated

24 May, 2024

Data

Company Financials +

JW (Cayman) Therapeutics Co. Ltd

DB:JNY Stock Report

Market Cap: €107.6m

JNY Stock Overview

A clinical stage cell therapy company, engages in the research and development, manufacturing, and marketing of anti-tumor drugs in the People’s Republic of China.

JNY fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

JW (Cayman) Therapeutics Co. Ltd Competitors

Price History & Performance

Summary of all time highs, changes and price drops for JW (Cayman) Therapeutics
Historical stock prices
Current Share PriceHK$0.25
52 Week HighHK$0.33
52 Week LowHK$0.18
Beta2.05
1 Month Change30.26%
3 Month Change13.39%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO13.49%

Recent News & Updates

Recent updates

Shareholder Returns

JNYDE BiotechsDE Market
7D-11.2%-1.2%-1.0%
1Yn/a-25.9%6.4%

Return vs Industry: Insufficient data to determine how JNY performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how JNY performed against the German Market.

Price Volatility

Is JNY's price volatile compared to industry and market?
JNY volatility
JNY Average Weekly Movement11.1%
Biotechs Industry Average Movement5.2%
Market Average Movement4.9%
10% most volatile stocks in DE Market10.7%
10% least volatile stocks in DE Market2.5%

Stable Share Price: JNY has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine JNY's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2016398James Liwww.jwtherapeutics.com

JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacturing, and marketing of anti-tumor drugs in the People’s Republic of China. It offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of a range of hematological cancers.

JW (Cayman) Therapeutics Co. Ltd Fundamentals Summary

How do JW (Cayman) Therapeutics's earnings and revenue compare to its market cap?
JNY fundamental statistics
Market cap€107.64m
Earnings (TTM)-€97.73m
Revenue (TTM)€22.12m

4.9x

P/S Ratio

-1.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
JNY income statement (TTM)
RevenueCN¥173.86m
Cost of RevenueCN¥85.64m
Gross ProfitCN¥88.22m
Other ExpensesCN¥856.22m
Earnings-CN¥768.00m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.90
Gross Margin50.74%
Net Profit Margin-441.74%
Debt/Equity Ratio15.6%

How did JNY perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.